These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 19450074

  • 21. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 22. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [Abstract] [Full Text] [Related]

  • 23. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [Abstract] [Full Text] [Related]

  • 24. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Jul; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 25. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 26. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R.
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [Abstract] [Full Text] [Related]

  • 27. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 28. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
    Palmer JL, Knudsen MS, Aagren M, Thomsen TL.
    J Med Econ; 2010 Jun; 13(2):212-20. PubMed ID: 20350145
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [Abstract] [Full Text] [Related]

  • 31. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
    Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P.
    Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
    [Abstract] [Full Text] [Related]

  • 32. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ, Pollock RF, Plun-Favreau J, White J.
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [Abstract] [Full Text] [Related]

  • 33. Biphasic insulin aspart 30 treatment improves glycemic control among patients with type 2 diabetes in Saudi Arabia and the Gulf region.
    Ayad NM, Fattah WA, Bakry H.
    Saudi Med J; 2008 Jun; 29(6):919-20. PubMed ID: 18521482
    [No Abstract] [Full Text] [Related]

  • 34. Technology and the issue of cost/benefit in diabetes.
    Giannini C, Mohn A, Chiarelli F.
    Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [Abstract] [Full Text] [Related]

  • 35. Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia.
    Alluhidan M, Alturaiki A, Alabdulkarim H, Aljehani N, Alghamdi EA, Alsabaan F, Alamri AA, Malkin SJP, Hunt B, Alhossan A, Al-Jedai A.
    Adv Ther; 2024 Nov; 41(11):4140-4152. PubMed ID: 39261418
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L, Christensen T, Sun F, Chang J.
    Value Health; 2012 Nov; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
    Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH.
    Scand J Public Health; 2011 Feb; 39(1):79-87. PubMed ID: 20688795
    [Abstract] [Full Text] [Related]

  • 38. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C, PROactive Study Group.
    Value Health; 2009 Feb; 12(1):1-9. PubMed ID: 18657104
    [Abstract] [Full Text] [Related]

  • 39. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.
    Pollock RF, Valentine WJ, Pilgaard T, Nishimura H.
    J Med Econ; 2011 Feb; 14(1):36-46. PubMed ID: 21192769
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.
    Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.